List of All Articles with Tag 'f'

Is non-English language music the future of the music business

SALT LAKE CITY--(BUSINESS WIRE)--Jul 12, 2023--

Wall Street is rallying after a report showed inflation cooled a bit more than expected last month

Burger King in Thailand have launched a bizarre new product - a “real cheeseburger” made with 20 slices of American cheese and no meat. The Thai operator of the US fast food chain announced that the burger was available at its outlets nationwide starting Sunday 9 July. Footage shows burger-lover Thanaporn Chatcharaporn, 26, tucking into the dish at a branch in Bangkok. “It’s very, very salty. Almost too salty to eat. The smell is also very strong. At the first bite, it gave me goosebumps, but I couldn’t finish the whole thing. I wanted to try it just to see what it was like,” she said. The glorified cheese sandwich costs around $3 - slightly cheaper than a regular meat cheeseburger. Read More Two teens found illegally smuggled in boot of car in Texas Passenger gets ‘private’ jet for £188 as no other travellers board flight Cancer survivor wears glittering eyeballs after losing left eye as baby

SAN FRANCISCO--(BUSINESS WIRE)--Jul 12, 2023--

With new research emerging, more questions have been raised about weight-loss injections, how they work, and the risks involved. Here are some of your questions answered. What are weight loss injections? Championed by some celebrities, including Elon Musk, weight loss injections were originally created to treat people with type 2 diabetes and other weight-related health issues. They are a type of prescription-based medical treatment that interferes with your metabolism, regulates your appetite and as a result encourages weight loss. The drugs belong to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, which mimic the GLP-1 hormone, released in the gut after eating some food. The only FDA-approved stomach injections to help with weight management are semaglutide — sold under the brand names Ozempic, Wegovy and Rybelsus — and liraglutide — sold under Saxenda. But others are in development. Helen Knight, programme director of the Centre for Health Technology Evaluation at the National Institute for Health and Care Excellence (Nice) said: “We know that management of overweight and obesity is one of the biggest challenges our health service is facing with nearly two-thirds of adults either overweight or obese. It is a lifelong condition that needs medical intervention, has psychological and physical effects, and can affect the quality of life. “But in recent years Nice has been able to recommend a new line of pharmaceutical treatments which have shown that those people using them, alongside changes to their diet and exercise, have been able to reduce their weight.” How do they work? According to Nice’s independent appraisal committee, drugs like semaglutide should only be prescribed to patients as an alternative for weight management — alongside a reduced-calorie diet and increased physical activity in adults. They should also have a BMI of at least 35.0 kg/m2 (this is medically classified as obese), and especially, to people with a BMI of 30.0 kg/m2 to 34.9 kg/m2, have non-diabetic hyperglycaemia (blood sugar that is above normal but below those needed to diagnose diabetes) or are at high risk of other weight-related conditions such as strokes and heart attacks, due to other factors such as high blood pressure and high cholesterol. Using semaglutide as an example, a typical dose for weight loss is 2.4 milligrams, administered weekly as under-the-skin self-injections. How are they going to be rolled out? Nice formally recommended liraglutide, orlistat and semaglutide as medicines suitable to use for weight loss earlier this year. And with such drugs also available through online pharmacies by private prescription, a growing number of people have tried the jabs. If they are prescribed alongside a reduced-calorie diet, increased physical activity, and behavioural support, after a year, people taking them can lose up to 15% of their body weight, with results visible within the first month, according to the Nice clinical trials. Some weight loss injections are available on the NHS, but they are only prescribed under certain circumstances. Following an announcement of a £40 million two-year pilot on June 7, the government have said more people living with obesity will have access to the newest and most effective obesity drugs to help cut NHS waiting lists. What are the possible side effects? Europe’s drug regulator The European Medicines Agency (EMA) is investigating whether patients using some weight loss and obesity jabs are at risk of suicidal thoughts and thoughts of self-harm, which highlights some of the controversy surrounding the phenomenon. The EMA safety committee said it is looking at cases among people who use a semaglutide or liraglutide-containing medicine for weight loss – where “signals” were raised by the Icelandic Medicines Agency. “A signal is information on a new or known adverse event that is potentially caused by a medicine and that warrants further investigation,” the EMA said. “The case reports included two cases of suicidal thoughts, one following the use of Saxenda and one after Ozempic. One additional case reported thoughts of self-injury with Saxenda. “The semaglutide-containing medicine Wegovy and the liraglutide-containing medicine Saxenda are authorised for weight loss, together with diet and physical activity. “Suicidal behaviour is not currently listed as a side-effect in the EU product information of these medicines.” If you have a history of medullary thyroid cancer, gallbladder disease, or even pancreatitis, you should avoid taking weight loss injections like semaglutide. People who do take the prescription drug for weight loss sometimes experience dizziness, fatigue, and gastrointestinal issues — the most common side effects among patients — such as diarrhoea, constipation and gassiness. They are also at risk of getting headaches and stomach conditions including vomiting, bloating and nausea. Read More Charity boss speaks out over ‘traumatic’ encounter with royal aide Ukraine war’s heaviest fight rages in east - follow live Journalist and author Yomi Adegoke on the real-life consequences of social media What is group B strep? Charity says pregnant women ‘in the dark’ Britney Spears: I worked my ass off to get my memoir written

Jordan Henderson is set to face a decision over whether to stay at Liverpool amid interest from Saudi Arabia and the possibility of a lucrative transfer. Liverpool are yet to receive an offer for their captain but Henderson has emerged as a target for Al Ettifaq and their new manager Steven Gerrard. Henderson, 33, has two years left on his contract at Anfield but could face a battle for his place after Jurgen Klopp spent £95m revamping his midfield with the signings of World Cup winner Alexis Mac Allister and Dominik Szoboszlai. Now Liverpool’s Champions League-winning skipper must determine whether to extend his 12-year stay at Anfield or join a host of players, including his former teammate Roberto Firmino, in signing up to go to Saudi Arabia. Euro 2024 is likely to be a factor in his thinking. Henderson forced his way back into England’s starting 11 during last winter’s World Cup and remains keen to play for his country. Klopp may be reluctant to lose the former Sunderland player, who made 43 appearances last season, after three other midfielders – vice-captain James Milner, Naby Keita and Alex Oxlade-Chamberlain – left at the end of the season. The 2020 Footballer of the Year succeeded Gerrard as Liverpool captain in 2015 and led them to their first English league title in three decades five years later. Read More The reason why Liverpool’s worst season under Jurgen Klopp can be a one-off Liverpool thought they’d bought the future – but two wrong moves left them counting the cost Why England will head into 2024 with their sense of optimism restored

Is non-English language music the future of the music business

Fulham reject offer from Saudi Pro League side Al Hilal for Aleksandar Mitrovic as they also battle to keep Marco Silva.

By Jorgelina do Rosario LONDON Global public debt surged to a record $92 trillion in 2022 as governments

U.S. financial regulators should take steps to ensure banks can withstand further interest-rate hikes should the Federal Reserve

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 12, 2023--